EGFR and cancer: Women have a lower risk of cancer-specific death (HR = 0.73; p < 0.00001). OS with EGFR is better in women (HR:0.34 vs. HR: 0.44). Similar OS with ALK (HR: 0.51 vs. HR: 0.48; p < 0.00001).